The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Androgen receptor (AR) is a major survival factor for prostate cancer (PCa). Inflammation is implicated in many cancer types including PCa. Activation of MAP3K7 (also termed TAK1) and downstream IκB kinase β (IKKβ) by pro-inflammatory cytokines such as TNFα stimulates NF-κB survival pathways. Paradoxically, MAP3K7 is often deleted in human PCa. Here we demonstrate that AR protein expression is lower in inflammatory tumor areas compared to non-inflammatory tissues in PCa patients. Via Cancer Research